Plain-English translation of NCT06451497 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new antibody medication designed to boost your immune system's ability to fight advanced cancers. You'll first receive alone, and later receive it combined with another immune therapy called toripalimab. This is an early-stage study (Phase 1) to find the right dose and learn how well this treatment works for people whose cancer has progressed despite standard therapies.
Many people with advanced cancers run out of standard treatment options or cannot tolerate available therapies. Researchers believe this medication could unlock a new way for the immune system to attack cancer cells, offering hope to patients who have limited choices left.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly to receive doses of the medication intravenously. The study has two parts: first, you'll receive alone at gradually increasing doses to find the safest level; then, eligible patients will receive combined with the second medication. Throughout the trial, you'll have blood tests, imaging scans, and physical exams to monitor how you're responding and check for side effects. The trial is expected to involve roughly 100 patients across multiple sites.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States